Articles related to LUNG CANCER

A community oncologist previewed four ASCO 2026 late-breaking abstracts spanning pancreatic, prostate, lung, and sarcoma, flagging molecular testing infrastructure and toxicity coordination as key implementation questions ahead of the data readout.

Invasive mucinous adenocarcinoma carries elevated NRG1 fusion burden that standard DNA-based sequencing reliably misses, while an FDA-approved targeted therapy now exists for confirmed cases.

Osimertinib plus datopotamab deruxtecan produced 20.5-month median duration of response at the 6 mg/kg dose in EGFR-mutated NSCLC after first-line osimertinib progression in the ORCHARD platform substudy.

Higher Healthy Eating Index scores and elevated oral contraceptive use co-occurred with young-onset lung cancer in a 187-patient nonsmoker cohort presented at AACR.

The current real-world cohort study examines long-term survival outcomes in the 5 years after a COVID-19 hospitalization for adults with a solid malignancy. The study assessed the impact of vaccination status, vaccine platform, primary tumor site, and cancer treatment.

“Second-line therapy should not be dismissed outright in platinum-refractory or early-relapsing disease. It remains a relevant part of comprehensive care.” — Tingting Tan, MD, PhD, City of Hope